Acasti Pharma Future Growth

Future criteria checks 0/6

Acasti Pharma is forecast to grow earnings and revenue by 22.6% and 165.7% per annum respectively while EPS is expected to grow by 56.3% per annum.

Key information

22.6%

Earnings growth rate

56.3%

EPS growth rate

Pharmaceuticals earnings growth	21.4%
Revenue growth rate	165.7%
Future return on equity	n/a
Analyst coverage	Low
Last updated	18 Apr 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:A1P0 - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2026	1	-19	-19	-19	1
3/31/2025	N/A	-17	-16	-16	1
3/31/2024	N/A	-14	-15	-15	1
12/31/2023	N/A	-39	-14	-14	N/A
9/30/2023	N/A	-40	-15	-15	N/A
6/30/2023	N/A	-42	-17	-17	N/A
3/31/2023	N/A	-42	-16	-16	N/A
12/31/2022	N/A	-17	-16	-16	N/A
9/30/2022	N/A	-17	-17	-17	N/A
6/30/2022	N/A	-11	-19	-19	N/A
3/31/2022	N/A	-10	-17	-17	N/A
12/31/2021	0	-12	-16	-16	N/A
9/30/2021	0	-11	-15	-15	N/A
6/30/2021	0	-18	-14	-14	N/A
3/31/2021	0	-20	-14	-14	N/A
12/31/2020	0	3	-16	-15	N/A
9/30/2020	N/A	-6	-19	-18	N/A
6/30/2020	N/A	-21	-21	-20	N/A
3/31/2020	N/A	-26	-23	-23	N/A
12/31/2019	N/A	-56	-29	-29	N/A
9/30/2019	N/A	-46	-29	-29	N/A
6/30/2019	N/A	-42	-27	-27	N/A
3/31/2019	N/A	-39	-25	-25	N/A
12/31/2018	N/A	-31	-20	-19	N/A
9/30/2018	N/A	-34	-17	-16	N/A
6/30/2018	N/A	-20	-13	-13	N/A
3/31/2018	N/A	-17	-10	-10	N/A
3/31/2017	N/A	-8	N/A	-5	N/A
11/30/2016	0	-7	N/A	-5	N/A
8/31/2016	0	-7	N/A	-5	N/A
5/31/2016	0	-6	N/A	-6	N/A
2/29/2016	N/A	-5	N/A	-5	N/A
11/30/2015	0	-5	N/A	-6	N/A
8/31/2015	0	-1	N/A	-6	N/A
5/31/2015	0	-3	N/A	-6	N/A
2/28/2015	N/A	-1	N/A	-6	N/A
11/30/2014	0	-2	N/A	-8	N/A
8/31/2014	0	-8	N/A	-7	N/A
5/31/2014	1	-8	N/A	-6	N/A
2/28/2014	0	-10	N/A	-6	N/A
11/30/2013	0	-10	N/A	-2	N/A
8/31/2013	1	-8	N/A	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: A1P0 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: A1P0 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: A1P0 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: A1P0 is forecast to have no revenue next year.

High Growth Revenue: A1P0 is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if A1P0's Return on Equity is forecast to be high in 3 years time

Acasti Pharma Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

No longer forecast to breakeven

Recent updates

Acasti Pharma Inc. to Attend BIO International Convention 2024

New major risk - Revenue and earnings growth

Acasti Pharma Inc. Announces Poster Detailing Its GTX-104 STRIVE-ON Trial

Acasti Pharma Inc. Approves Appointment of Robert J. Delaversano, as Principal Financial Officer and Principal Accounting Officer

Acasti Pharma Inc. Announces Board Changes

New minor risk - Shareholder dilution

Independent Chairman recently bought €1.2m worth of stock

Acasti Pharma Inc. announced that it has received $7.499388 million in funding from S S Pharma Llc, Shore Pharma Llc

Acasti Pharma Inc., Annual General Meeting, Sep 28, 2023

Acasti Pharma Announces 1-For-6 Reverse Stock Split to Regain Compliance with the $1.00 Minimum Bid Price Continued Listing Requirement of the Nasdaq Capital Market

Acasti Pharma Inc. Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol

Acasti Pharma Inc. Announces Scientific Advisory Board Appointments

High number of new and inexperienced directors

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Second Quarter 2025

High number of new and inexperienced directors

Acasti Pharma Inc. to Report Q3, 2023 Results on Feb 14, 2023

Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule

Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia

Acasti Pharma Inc. Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)

High number of new and inexperienced directors

Acasti Pharma Inc. to Report Q2, 2023 Results on Nov 14, 2022

Acasti Pharma Inc. Announces Board Changes

Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, Drug Candidate for the Treatment of Ataxia Telangiectasia

Acasti Pharma Inc. to Report Q1, 2023 Results on Aug 11, 2022

Acasti Pharma Inc., Annual General Meeting, Sep 28, 2022

Acasti Pharma Inc. Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia

No longer forecast to breakeven

Acasti Pharma Announces the Issuance of Additional Patents for GTX-104 and GTX-101

Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints

Less than half of directors are independent

Less than half of directors are independent

Acasti Pharma Inc. Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104

Acasti Pharma Inc. Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, its Lead Drug Candidate for Treatment of Subarachnoid Hemorrhage

Acasti Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Insufficient new directors

Insufficient new directors

Acasti Pharma Inc. (TSXV:ACST) completed the acquisition of Grace Therapeutics, Inc.

Acasti Intends to Request Hearing Before Nasdaq Panel to Present Plan of Compliance

Acasti Pharma Inc. (TSXV:ACST) entered into a definitive agreement to acquire Grace Therapeutics, Inc. for $71.4 million.

New 90-day high: €0.72

New 90-day high: €0.47

New 90-day high: €0.46

New 90-day high: €0.24

Acasti Pharma Inc. Announces Resignation of Brian Groch as Chief Commercial Officer, Effective December 31, 2020

Acasti Pharma Inc. Announces Executive Changes

New 90-day low - €0.25

Acasti Pharma Inc. Auditor Raises 'Going Concern' Doubt

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies